Page last updated: 2024-12-05

dimethylformamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dimethylformamide: A formamide in which the amino hydrogens are replaced by methyl groups. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N,N-dimethylformamide : A member of the class of formamides that is formamide in which the amino hydrogens are replaced by methyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6228
CHEMBL ID268291
CHEBI ID17741
MeSH IDM0006462

Synonyms (210)

Synonym
BIDD:ER0600
nsc-5356
nsc5356
u-4224
n-formyldimethylamine
dimetilformamide
wln: vhn1&1
dimethylformamide
formamide,n-dimethyl-
dimethylformamid
dmfa
dmf (amide)
dwumetyloformamid
dimethylforamide
CHEBI:17741 ,
formamide, n,n-dimethyl-
formamide, dimethyl-
n,n-dimethyl formamide
dimethyl formamide
formin acid,amide,n,n-dimethyl
inchi=1/c3h7no/c1-4(2)3-5/h3h,1-2h
NCGC00090785-02
NCGC00090785-01
dimetylformamidu [czech]
ccris 1638
n,n-dimetilformamida [spanish]
dimethylamid kyseliny mravenci [czech]
un2265
formyldimethylamine
dwumetyloformamid [polish]
formic acid, amide, n,n-dimethyl-
ai3-03311
hsdb 78
nsc 5356
epa pesticide chemical code 366200
dimetilformamide [italian]
einecs 200-679-5
caswell no. 366a
dimethylformamid [german]
nci-c60913
n,n-dimethylformamide
C03134
DMF ,
68-12-2
n,n-dimethylmethanamide
n,n-dimethylformamide, for molecular biology, >=99%
n,n-dimethylformamide, acs reagent, >=99.8%
n,n-dimethylformamide, aldrasorb(tm), 99.8%
DB01844
NCGC00090785-03
n,n dimethylformamide
n,n-dimethylformamide, for hplc, >=99.9%
n,n-dimethylformamide, anhydrous, 99.8%
D0939
D0722
CHEMBL268291
BMSE000709
FT-0696040
AKOS000121096
A836012
NCGC00090785-04
NCGC00090785-05
cas-68-12-2
dtxsid6020515 ,
NCGC00258811-01
tox21_201259
dtxcid20515
NCGC00254093-01
tox21_300039
n,n-dimethylformamid
n,n-dimethylformamide [un2265] [flammable liquid]
dimethylamid kyseliny mravenci
ec 200-679-5
dimetylformamidu
unii-8696nh0y2x
8696nh0y2x ,
n,n-dimetilformamida
FT-0629533
FT-0639029
FT-0629532
S6192
STL264197
n,n-dimethylformamide [mi]
dimethylformamide [mart.]
n,n-dimethylformamide [iarc]
n,n-dimethylformamide [usp-rs]
n,n-dimethylformamide [hsdb]
n,n-dimethylformamide [who-dd]
n,n-dimethylformamide, acs grade
n, n-dimethyl formamide
dimethylformamide-
dimetylformamide
n,n-dimethylforamide
dimethylformarnide
n,n-dimetyl formamide
n,n-dimethvlformamide
n,n-dimethyl formamid
n,n-dimethylformarnide
n,n- dimethylformamide
n,n-dimethylform-amide
n,n'dimethylformamide
dimethylf ormamide
n,n -dimethylformamide
n, n dimethylformamide
n,n-dimethy formamide
n, n-dimethylforamide
n,n-dimethyl -formamide
n,n-dimehtyl formamide
n,n-di-methyl-formamide
n,n-dimethylformaldehyde
n, n- dimethylformamide
n.n-dimethylformamide
n,n-dime-thylformamide
n, n'-dimethylformamide
dimethylformamid e
dimethyl- formamide
dimethy formamide
n,n-dimethyl- formamide
n,n-dimethylfor-mamide
dimethyl form-amide
n, n-dimethyl-formamide
dimethyl foramide
n,n.dimethylformamide
dimethlforamide
dimethy1formamide
n,n-dirnethylformamide
n,n-di-methylformamide
n,n-dimethylformamide-
n,n,-dimethyl formamide
dirnethylformamide
dimethylfor- mamide
d.m.f
n,n-dimethyl-formamide
n,n,-dimethylformamide
dimehtylformamide
d.m.f.
n,n-dimethl formamide
hconme2
dimethylform amide
dimehtylformarnide
n, n-dimethylformaldehyde
dimethlyformamide
n,n,dimethylformamide
n, n-di-methylformamide
n,n'-dimethylforamide
dirnethylformarnide
n,n-dimethlformamide
dimethyl-formamide
n,n-dimethylfor mamide
n,n dimethyl formamide
dimethyiformamide
n,n-di-methylforrnamide
n,n-dimethylforrnamide
dimethylforrnamide
n,n-dimetylformamide
n,n-di methylformamide
n,n-di-methyl formamide
di-methylformamide
dimethlformamide
dimethyl formamid
n,n-dimethyl foramide
dimethylform-amide
n,n' dimethylformamide
n,n-dimethyformamide
n, n-dimethylformamide
dimethyformamide
mfcd00003286
un 2265
dmf (dimethylformamide)
dynasolve 100 (salt/mix)
hcon(ch3)2
mfcd00003284
n,n-dimethylformamide, hplc grade
n,n-dimethylformamide, spectrophotometric grade
n,n-dimethylformamide hplc grade
n,n-dimethylformamide, analytical standard
n,n-dimethylformamide, anhydrous
n,n-dimethylformamide, anhydrous, amine free
n,n-dimethylformamide, acs spectrophotometric grade, >=99.8%
n,n-dimethylformamide, saj first grade, >=99.0%
n,n-dimethylformamide, puriss. p.a., acs reagent, reag. ph. eur., >=99.8% (gc)
n,n-dimethylformamide, jis special grade, >=99.5%
n,n-dimethylformamide, biotech. grade, >=99.9%
n,n-dimethylformamide, suitable for neutral marker for measuring electroosmotic flow (eof), ~99%
n,n-dimethylformamide, reagentplus(r), >=99%
n,n- dimethyl formamide
n,n-dimethylformamide, anhydrous, zero2(tm), 99.8%
dmf,sp grade
n,n-dimethylformamide, 99.8%
n,n-dimethylformamide, p.a., acs reagent, reag. iso, reag. ph. eur., 99.8%
dimethylformamide, pharmaceutical secondary standard; certified reference material
n,n-dimethylformamide hplc, uv-ir min. 99.9%, isocratic grade
n,n-dimethylformamide, uv hplc spectroscopic, 99.7%
n,n-dimethylformamide, p.a., 99.8%
n,n-dimethylformamide, lr, >=99%
n,n-dimethylformamide, vetec(tm) reagent grade, anhydrous, >=99.8%
n,n-dimethylformamide, for hplc, >=99.5%
n,n-dimethylformamide, p.a., acs reagent, 99.8%
n,n-dimethylformamide, ar, >=99.5%
dmf; dimethylformamide; n,n-dimethylformamide
Q409298
n,n-dimethylformamide-1-d
dimethyl fornamide,(s)
n-dimethylformamide
n,n-dimethylformamide, biotech grade
dimethylformamide (mart.)
n,n-dimethylformamide (iarc)
usepa/opp pesticide code: 366200
SY010600
Z220615596

Research Excerpts

Overview

N,N-dimethylformamide (DMF) is a non-negligible volatile hazardous material in indoor and outdoor environments. It is a widely existing harmful environmental pollutant from industrial emission which can threat human health for both occupational and general populations.

ExcerptReferenceRelevance
"N,N-dimethylformamide (DMF) is a widely-used solvent for the synthesis of synthetic fibers such as polyacrylonitrile fiber, and can also be used to make medicine. "( Exposure of mouse oocytes to N,N-dimethylformamide impairs mitochondrial functions and reduces oocyte quality.
Fei, CF; Guo, SM; He, X; Yin, Y; Zhou, LQ, 2022
)
1.56
"N,N-dimethylformamide (DMF) is a non-negligible volatile hazardous material in indoor and outdoor environments. "( N,N-dimethylformamide-induced acute liver damage is driven by the activation of NLRP3 inflammasome in liver macrophages of mice.
Guo, FF; Li, LX; Li, MJ; Liu, H; Wang, S; Zeng, T; Zhang, XN, 2022
)
1.84
"N, N-dimethylformamide (DMF) is a widely existing harmful environmental pollutant from industrial emission which can threat human health for both occupational and general populations. "( N, N-dimethylformamide exposure induced liver abnormal mitophagy by targeting miR-92a-1-5p-BNIP3L pathway in vivo and vitro.
Chen, N; Jin, Y; Li, C; Luo, J; Ma, W; Sun, X; Xu, L; Yu, D; Zhao, K; Zheng, Y; Zhu, X, 2022
)
1.75
"N,N-Dimethylformamide (DMF) is an organic solvent produced in large quantities worldwide. "( Long-term biofiltration of gaseous N,N-dimethylformamide: Operational performance and microbial diversity analysis at different conditions.
Boon, N; Demeestere, K; Lamprea Pineda, PA; Toledo, M; Van Langenhove, H; Walgraeve, C, 2023
)
1.74
"N,N-dimethylformamide is a toxic chemical solvent, which widely exists in industrial wastewater. "( Biosynthesis of poly(3-hydroxybutyrate) by N,N-dimethylformamide degrading strain Paracoccus sp. PXZ: A strategy for resource utilization of pollutants.
Cai, S; Cai, T; Chen, L; Ji, XM; Pan, J; Zhao, L, 2023
)
1.73
"N,N-Dimethylformamide (DMF) is a widespread contaminant of leather factories and their surrounding environment. "( The essential role of CYP2E1 in metabolism and hepatotoxicity of N,N-dimethylformamide using a novel Cyp2e1 knockout mouse model and a population study.
Cheng, J; Guan, M; Leng, S; Liu, Q; Lu, S; Wang, C; Wang, L; Wu, Z; Zhang, M; Zhao, W; Zheng, M, 2019
)
1.31
"N,N-dimethylformamide (DMF) is a colorless industrial solvent that is frequently used for chemical reactions. "( Retinoid X receptor α (RXRα)-mediated erythroid-2-related factor-2 (NRF2) inactivation contributes to N,N-dimethylformamide (DMF)-induced oxidative stress in HL-7702 and HuH6 cells.
Chang, C; He, Q; Jiang, H; Li, R; Liu, Y; Liu, Z; Wang, Q; Zhang, Z, 2020
)
1.33
"N, N-Dimethylformamide (DMF) is a universal organic solvent which widely used in various industries, and a considerable amount of DMF is detected in industrial effluents. "( Integration of proteomics, lipidomics, and metabolomics reveals novel metabolic mechanisms underlying N, N-dimethylformamide induced hepatotoxicity.
Chen, J; Feng, M; Hou, Y; Jin, Y; Li, C; Luo, J; Ma, W; Wang, Y; Xu, L; Yu, D; Zhao, J; Zhao, Q; Zheng, Y, 2020
)
1.29
"Dimethylformamide (DMF) is an excellent solvent widely used in biology, medicine and other fields."( Dimethylformamide Inhibits Fungal Growth and Aflatoxin B
Chang, P; Jin, J; Pan, L; Xing, F; Yang, Q, 2020
)
2.72
"N,N-dimethylformamide (DMF) is an organic compound widely used in industrial production processes as a solvent with a low evaporation rate. "( Hsa_circ_0005915 promotes N,N-dimethylformamide-induced oxidative stress in HL-7702 cells through NRF2/ARE axis.
Chen, L; Chen, S; Chen, W; Cui, M; He, Q; Li, D; Liu, Y; Liu, Z; Peng, H; Wang, Q; Wang, Y; Xiao, Y; Zhang, Y, 2021
)
1.47
"N,N-dimethylformamide (DMF) is a versatile solvent with wide industrial applications. "( The deleterious effects of N,N-dimethylformamide on liver: A mini-review.
Li, MJ; Zeng, T, 2019
)
1.36
"Dimethylformamide (DMF) is a broad solvent used in the production of synthetic leather. "( Risk assessment of N,N-dimethylformamide on residents living near synthetic leather factories.
Huang, C; Tian, W; Wang, C; Wei, Y; Zhang, Q; Zhu, Q, 2014
)
2.16
"N, N-dimethylformamide (DMF) is a toxic solvent that is widely used in many industries. "( Chronic occupational N, N-dimethylformamide poisoning induced death: a case report.
Dong, H; Duan, Y; Liu, Q; Zhang, H; Zhou, Y, 2015
)
1.23
"N, N-Dimethylformamide (DMF) is a widely used organic solvent whose wastewater is difficult to biodegrade directly. "( A novel chemical/biological combined technique for N, N-dimethylformamide wastewater treatment.
Chen, Y; Li, B; Qiu, Y; Shen, S; Xu, X, 2016
)
1.19
"N,N-dimethylformamide (DMF) is a man-made compound that is widely used as a solvent for the synthesis of various organic compounds. "( Biomineralization of N,N-dimethylformamide by Paracoccus sp. strain DMF.
Ramanathan, G; Sughosh, P; Swaroop, S, 2009
)
1.21
"N,N-dimethylformamide (DMF) is a solvent used extensively in the chemical industry. "( Occupational liver injury due to N,N-dimethylformamide in the synthetics industry.
Abe, M; Hamada, M; Hiasa, Y; Matsuura, B; Miyake, T; Murakami, H; Onji, M; Sato, K; Tokumoto, Y, 2009
)
1.18
"N,N-Dimethylformamide (DMF) is an organic solvent extensively used in industries such as synthetic leather, fibers and films, and induces liver toxicity and carcinogenesis. "( Synergistic hepatotoxicity of N,N-dimethylformamide with carbon tetrachloride in association with endoplasmic reticulum stress.
Kim, CW; Kim, SG; Kim, TH; Kim, YW; Shin, SM; Yu, IJ, 2010
)
1.2
"N,N-dimethylformamide (DMF) is a colorless liquid with a faint amine odor, which is widely used in the world. "( Liver and heart toxicity due to 90-day oral exposure of ICR mice to N,N-dimethylformamide.
Daojun, C; Rui, D; Yongjian, Y, 2011
)
1.16
"N,N-Dimethylformamide (DMF) is a dipolar protophilic solvent with physicochemical properties that makes it suitable as solvent for capillary electrophoresis (CE). "( Capillary electrophoresis in N,N-dimethylformamide.
Kenndler, E; Porras, SP, 2005
)
1.17
"N,N-Dimethylformamide (DMF) is a well-known chemical entity that is extensively used for pharmaceutical, biomedical and chemical applications. "( Development of an analytical method for the evaluation of N,N-dimethylformamide in dosage form design.
Du Toit, D; Hamman, JH; Olivier, EI, 2007
)
1.14
"Dimethylformamide (DMF) is an industrial solvent with hepatotoxic properties. "( Investigation of the mechanistic basis of N,N-dimethylformamide toxicity. Metabolism of N,N-dimethylformamide and its deuterated isotopomers by cytochrome P450 2E1.
Gescher, A; Hyland, R; Jheeta, P; Mráz, J; Threadgill, MD; Thummel, K,
)
1.83
"N,N-dimethylformamide (DMF) is a commonly used industrial solvent. "( N-methylcarbamoyl adducts at the N-terminal valine of globin in workers exposed to N,N-dimethylformamide.
Angerer, J; Göen, T; Käfferlein, HU; Krämer, A, 1998
)
1.08
"N,N-dimethylformamide (DMF) is a solvent that is widely used in industry. "( [Measurement of N-methylformamide in occupational exposure to N,N-dimethylformamide].
Abatangelo, L; Cavalleri, A; Ghittori, S; Imbriani, M; Marraccini, P; Saretto, G,
)
0.93
"Dimethylformamide (DMF) is a universal solvent noted for its solubility in both aqueous and lipid media. "( Biological monitoring of workers exposed to dimethylformamide in a textile polyurethane unit.
Adejoro, B; King, B; Osunsanya, T, 2001
)
2.01
"Dimethylformamide (DMF) is a widely used industrial solvent. "( Developmental toxicity of dimethylformamide in the rat following inhalation exposure.
Kennedy, GL; Lewis, SC; Schroeder, RE, 1992
)
2.03

Effects

N,N-Dimethylformamide (DMF) has been suspected to associate with cancers in exposed workers. There has been inadequate evidence for carcinogenicity in experimental animals. Dimethyl formamide has been used as a model inducer in carcinoma and fibroblastic models.

ExcerptReferenceRelevance
"N,N-Dimethylformamide (DMF) has been widely used in industries because of its extensive miscibility with water and solvents. "( Mitochondrial DNA alterations in blood of the humans exposed to N,N-dimethylformamide.
Chang, HY; Chen, CC; Shieh, DB; Shih, TS; Tai, HM; Wei, YH, 2007
)
1.13
"Dimethylformamide (DMF) has been suspected to associate with cancers in exposed workers, whereas there has been inadequate evidence for carcinogenicity in experimental animals. "( DNA damage by dimethylformamide: role of hydrogen peroxide generated during degradation.
Kawanishi, S; Midorikawa, K; Murata, M; Oikawa, S; Tada-Oikawa, S, 2000
)
2.11
"N,N-Dimethylformamide (DMF) has excellent solvent properties and is used intensively in the production of synthetic leather and resins. "( Abnormal liver function associated with occupational exposure to dimethylformamide and hepatitis B virus.
Chang, MJ; Cheng, TJ; Kuo, HW; Luo, JC, 2001
)
1.11
"N,N-Dimethylformamide (DMF) has been implicated in the production of hepatotoxicity in male and female F344 rats. "( Histopathological investigation of DMF-induced hepatotoxicity.
Itoh, H; Oikawa, K; Uchikoshi, T, 1987
)
0.83
"Dimethylformamide has been used as a model inducer in carcinoma and fibroblastic models."( Alkylformamides as inducers of tumour cell differentiation--a mini-review.
Hickman, JA; Langdon, SP, 1987
)
0.99

Actions

ExcerptReferenceRelevance
"Dimethylformamide can cause liver damage even if air concentration is in the sub-threshold limit value (sub-TLV) level. "( Serum activities of liver enzymes in workers exposed to sub-TLV levels of dimethylformamide.
He, J; Kong, Y; Liu, J; Yang, W; Zhang, Z, 2015
)
2.09

Treatment

ExcerptReferenceRelevance
"N,N-Dimethylformamide treatment of cell cultures established from a transplantable murine rhabdomyosarcoma-induced morphological differentiation and a marked reduction in the tumorigenicity of the sarcoma cells. "( N,N-Dimethylformamide-induced morphological differentiation and reduction of tumorigenicity in cultured mouse rhabdomyosarcoma cells.
Dexter, DL, 1977
)
1.37

Toxicity

The aerobic sequencing batch activated sludge system (SBR) was used to remove the toxic and refractory organic pollutant N,N-dimethylformamide (DMF)

ExcerptReferenceRelevance
" The results are tabulated as LD50 ml/kg with 95% confidence limits."( Acute toxicity of various solvents in the mouse and rat. LD50 of ethanol, diethylacetamide, dimethylformamide, dimethylsulfoxide, glycerine, N-methylpyrrolidone, polyethylene glycol 400, 1,2-propanediol and Tween 20.
Bartsch, W; Dietmann, K; Fuchs, G; Sponer, G, 1976
)
0.48
" It was concluded that the only form of AmB toxic to human erythrocytes is the water-soluble self-associated form (in contrast with fungal cells on which the monomeric form is also active)."( Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes.
Bolard, J; Cohen, BE; Legrand, P; Romero, EA, 1992
)
0.28
" Based on extensive monitoring of the monkeys' clinical condition, semen quantity and quality, and clinical and pathological evaluations, no exposure-related adverse health effects were detected following exposure to concentrations of DMF ranging from 30 to 500 ppm for 13 weeks."( 13-week inhalation toxicity study of dimethylformamide (DMF) in cynomolgus monkeys.
Hurtt, ME; Kennedy, GL; Killinger, JM; Placke, ME; Singer, AW, 1992
)
0.56
" DMF did not produce malformations in the rat fetus even at a level that was toxic to the dam."( Developmental toxicity of dimethylformamide in the rat following inhalation exposure.
Kennedy, GL; Lewis, SC; Schroeder, RE, 1992
)
0.58
" DMAC was slightly more toxic with all treated rabbits dying of acute hepatic necrosis."( Acute and subchronic toxicity of dimethylformamide and dimethylacetamide following various routes of administration.
Kennedy, GL; Sherman, H, 1986
)
0.55
" Comparison of the acute toxicity of DMF, DMF-OH and NMF shows that NMF is more toxic than DMF-OH, which is itself more toxic than DMF."( In vivo metabolism of dimethylformamide and relationship to toxicity in the male rat.
Lauwerys, R; Scailteur, V, 1984
)
0.58
" The toxic properties of this substance are reviewed from the standpoint of industrial hygiene."( [The toxicity of N,N-dimethylformamide (DMF)].
Tanaka, K; Utsunomiya, T, 1982
)
0.58
" The single tested solvents did not show any major differences in acute toxicity in the three tested strains with the exclusion of DMSO (less toxic in CD2F1) and BeOH and EtOH (less toxic in B6D2F1)."( Acute intravenous toxicity of dimethyl sulfoxide, polyethylene glycol 400, dimethylformamide, absolute ethanol, and benzyl alcohol in inbred mouse strains.
Cavalletti, E; Melloni, E; Montaguti, P, 1994
)
0.52
"7 mmol/kg DMF, HMMF, or NMF showed i) that DMF is more toxic than HMMF or NMF, and ii) that hepatotoxicity occurs later for DMF than for HMMF or NMF."( Metabolism and hepatotoxicity of N,N-dimethylformamide, N-hydroxymethyl-N-methylformamide, and N-methylformamide in the rat.
Belpaire, FM; Buylaert, W; Rosseel, MT; Van den Bulcke, M; Wijnants, P, 1994
)
0.56
" It is proposed that the presence of such selectively toxic compounds in the diet may inhibit the development of tumors by interfering with the growth of preneoplastic lesions while having little effect on normal cells."( Selective toxicity of compounds naturally present in food toward the transformed phenotype of human colorectal cell line HT29.
Fyfe, D; Johnson, IT; Musk, SR; Smith, TK; Stening, P; Stephenson, P, 1995
)
0.29
" Exposure to DMF at doses of 1/10 and 1/160 LD50 could significantly cause decrease of IL-2 release."( [Studies on cell-mediated immunotoxicity of dimethylformamide].
Gao, X; Qiao, C; Zhang, W, 1996
)
0.56
" First convincingly introduced by Baxter and Lathe in 1971, the concept that certain amides can block toxic effects of dimethyl sulfoxide (Me(2)SO) was contradicted by direct experiments in 1990."( Cryoprotectant toxicity neutralization.
Fahy, GM, 2010
)
0.36
" The ultimate goal was to select safe dispersing media and enrich the database of C(60) nanotoxicity for NanoQuantitative-Structure-Activity-Relationship (NanoQSAR) applications."( Choosing safe dispersing media for C60 fullerenes by using cytotoxicity tests on the bacterium Escherichia coli.
Aker, WG; Cook, SM; Hwang, HM; Jenkins, JJ; Leszczynski, J; Rasulev, BF; Shockley, V, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" DMF exposure may induce adverse effects on liver, but few studies showed damage to heart after exposure to DMF."( Liver and heart toxicity due to 90-day oral exposure of ICR mice to N,N-dimethylformamide.
Daojun, C; Rui, D; Yongjian, Y, 2011
)
0.6
" In this work, the antinociceptive and toxic effects of two new coordination complexes: Cu₂(fen)₄(caf)₂ [fen: fenoprofenate anion; caf: caffeine] and Cu₂(fen)₄(dmf)₂ [dmf: N-N'-dimethylformamide] were evaluated in mice."( Anti-nociceptive activity and toxicity evaluation of Cu(II)-fenoprofenate complexes in mice.
Agotegaray, M; Bras, C; Gandini, NA; Gumilar, F; Minetti, A; Quinzani, O, 2012
)
0.57
" These recommendations are based on evidence of adverse solvent effects in apical level tests."( Implications of the solvent vehicles dimethylformamide and dimethylsulfoxide for establishing transcriptomic endpoints in the zebrafish embryo toxicity test.
Cossins, A; Fenske, M; Sawle, A; Turner, C, 2012
)
0.65
"The aerobic sequencing batch activated sludge system (SBR) was used to remove the toxic and refractory organic pollutant, N,N-dimethylformamide (DMF)."( [Research on sludge toxicity caused by DMF biodegradation and toxicity spatial distribution in sludge flocs].
Ai, QF; Chen, SJ; Chen, XR; Ding, Y; Hu, YY; Huang, H; Wang, LP; Xu, WL; Yang, N, 2013
)
0.6
" Accumulating animal and epidemiological studies have identified liver injury as an early toxic effect of DMF exposure; however, the detailed mechanisms remain poorly understood."( Integration of proteomics, lipidomics, and metabolomics reveals novel metabolic mechanisms underlying N, N-dimethylformamide induced hepatotoxicity.
Chen, J; Feng, M; Hou, Y; Jin, Y; Li, C; Luo, J; Ma, W; Wang, Y; Xu, L; Yu, D; Zhao, J; Zhao, Q; Zheng, Y, 2020
)
0.77

Pharmacokinetics

ExcerptReferenceRelevance
" Area under the plasma concentration curve (AUC) values were determined following exposure for DMF and "N-methylformamide" ["NMF" represented N-methylformamide plus N-(hydroxymethyl)-N-methylformamide (DMF-OH)]."( Dimethylformamide pharmacokinetics following inhalation exposures to rats and mice.
Hundley, SG; Kennedy, GL; Lieder, PH; Malley, LA; Valentine, R, 1993
)
1.73
" Area under the plasma concentration curve (AUC) values were determined for DMF and "NMF" [N-methylformamide (NMF) plus N-(hydroxymethyl)-N-methylformamide (DMF-OH)]."( Dimethylformamide pharmacokinetics following inhalation exposure in monkeys.
Hundley, SG; Hurtt, ME; Kennedy, GL; Lieder, PH; McCooey, KT, 1993
)
1.73

Compound-Compound Interactions

ExcerptReferenceRelevance
" For more preconcentration, the developed procedure was combined with a dispersive liquid-liquid microextraction procedure."( Development of a pH-induced dispersive solid-phase extraction method using folic acid combined with dispersive liquid-liquid microextraction: application in the extraction of Cu(II) and Pb(II) ions from water and fruit juice samples.
Farajzadeh, MA; Parvizzad, K; Sorouraddin, SM, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
"The occluded vasoconstrictor assay was used to assess the effect of penetration enhancers on the topical bioavailability of a representative steroid, betamethasone 17-benzoate, with dimethylisosorbide (DMI) as a reference solvent."( Optimization of bioavailability of topical steroids: penetration enhancers under occlusion.
Barry, BW; Southwell, D; Woodford, R, 1984
)
0.27
" To determine factors necessary for bioactivity, we tested the cytotoxicity of different ligand compounds in conjunction with speciation studies and mass spectrometry bioavailability measurements."( Cytotoxicity of a Ti(IV) compound is independent of serum proteins.
Incarvito, CD; Saghatelian, A; Thomas, HR; Tinoco, AD; Valentine, AM, 2012
)
0.38
" The project team was able to improve the bioavailability by reducing efflux through systematic modifications to the strength of the HBA by changing the electronic properties of neighboring groups, whilst maintaining sufficient acceptor strength for potency."( Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.
Eisman, MS; Gu, C; Harrison, RA; Hu, H; Johannes, JW; Kazmirski, S; Lamb, ML; Lyne, PD; Mikule, K; Peng, B; Scott, DA; Su, N; Sylvester, MA; Wang, W; Ye, Q; Zheng, X, 2016
)
0.43

Dosage Studied

Male Wistar rats were dosed with N,N-dimethylformamide (DMF) in drinking water at four concentration levels. metabolic profiles for aniline (A), chloroform (CL), ethylbenzene (EB), 2-methoxyethanol (ME) and tetrahydrofurane (THF) were compared to oral dosing.

ExcerptRelevanceReference
" One female in the high dosage group died on Gestation Day 12."( Evaluation of teratogenic potential of N-formylpiperidine in rats.
Alvarez, L; Johannsen, FR; Nair, RS, 1992
)
0.28
" When using 12 concentration levels, one of the logistic family two- or three-parameter models was shown reliably to represent each of these various sets of dose-response data, and to provide adequate estimates of EC01 and EC05, as well as EC10 and EC50."( A study of the shape of dose-response curves for acute lethality at low response: a "megadaphnia study".
Adams, WJ; Sebaugh, JL; Tucker, MW; Wilson, JD, 1991
)
0.28
" In rabbits dermal administration led to a steeper increase in the dose-response relationship and at 400 mg/kg body weight/day to a clear teratogenic effect in the presence of slight maternal toxicity."( Studies on the prenatal toxicity of N,N-dimethylformamide in mice, rats and rabbits.
Hellwig, J; Jäckh, R; Klimisch, HJ; Merkle, J, 1991
)
0.55
" The rats were dosed on gestation days 6-15 or on gestation days 1-20 at dose levels of up to 2 ml DMF kg-1 body weight."( Embryotoxicity and teratogenicity study in rats dosed epicutaneously with dimethylformamide (DMF).
Hansen, E; Meyer, O, 1990
)
0.51
" No dose-response relationships were observed between DMF or ACN exposure and cancer incidence."( Cancer incidence of workers exposed to dimethylformamide and/or acrylonitrile.
Chen, JL; Fayerweather, WE; Pell, S, 1988
)
0.54
" No dose-response relationships were observed between DMF or ACN exposure and mortality."( Mortality study of workers exposed to dimethylformamide and/or acrylonitrile.
Chen, JL; Fayerweather, WE; Pell, S, 1988
)
0.55
"Male Wistar rats were dosed with N,N-dimethylformamide (DMF) in drinking water at four concentration levels (0,0."( N,N-Dimethylformamide-induced effects on hepatic and renal xenobiotic enzymes with emphasis on aldehyde metabolism in the rat.
Elovaara, E; Marselos, M; Vainio, H, 1983
)
1.1
" These observations occurred in a dose-response fashion and were minimal at 25 ppm."( Chronic toxicity/oncogenicity of dimethylformamide in rats and mice following inhalation exposure.
Elliott, GS; Kennedy, GL; Malley, LA; Ross, PE; Slone, TW; Stadler, JC; Van Pelt, C, 1994
)
0.57
" Fifty percent effective doses (ED50) to block propagated compound action potentials (AP's) were obtained by examining dose-response relations for each solute."( An analysis of dimethylsulfoxide-induced action potential block: a comparative study of DMSO and other aliphatic water soluble solutes.
Gasser, K; Hahin, R; Larsen, J, 1996
)
0.29
" The participation of alpha2-adrenergic receptors in the sedative effect provoked by amitraz was studied by dosing yohimbine (0."( Characterization of the antinociceptive and sedative effect of amitraz in horses.
Carregaro, AB; Gonçalves, SC; Harkins, JD; Mataqueiro, MI; Queiroz-Neto, A; Tobin, T; Zamur, G, 1998
)
0.3
" This study examined the dose-response relationship of the observed abnormal liver function among the DMF-exposed workers and the interactions among DMF, other chemical exposures, HBV infection, and potential confounders on liver abnormalities."( Abnormal liver function associated with occupational exposure to dimethylformamide and hepatitis B virus.
Chang, MJ; Cheng, TJ; Kuo, HW; Luo, JC, 2001
)
0.55
"The features of apoptotic dose responses typically have been evaluated over a broad dose-response continuum to differentiate apoptotic and necrotic responses."( Apoptosis: biphasic dose responses.
Calabrese, EJ, 2001
)
0.31
" Dose-response analyses were performed with dinitrobenzene sulfonic acid (DNBS) and formaldehyde formulated either in water, 1% L92, dimethyl sulfoxide (DMSO) or dimethyl formamide (DMF)."( Examination of a vehicle for use with water soluble materials in the murine local lymph node assay.
Cruse, LW; Dearman, RJ; Gerberick, GF; Kimber, I; Ryan, CA; Skinner, RA, 2002
)
0.31
" Motility parameters were related to urinary NMF in a dose-response manner but were not related to airborne DMF."( Sperm function in workers exposed to N,N-dimethylformamide in the synthetic leather industry.
Chang, HY; Guo, YL; Hsu, PC; Shih, TS; Tsai, CY, 2004
)
0.59
" Previously, the authors demonstrated the significant dose-response relationship between abnormal liver function tests and DMF exposure and the interaction with hepatitis B virus (HBV) infection in Taiwanese workers."( Abnormal liver function associated with occupational exposure to dimethylformamide and glutathione S-transferase polymorphisms.
Chang, MJ; Cheng, TJ; Kuo, HW; Luo, JC,
)
0.37
" Enhancement ratios were higher at 24 h for 10 than for 6 g/kg animals, demonstrating a dose-response relationship for recovery time."( A single oral dose of ethanol can alter transdermal absorption of topically applied chemicals in rats.
Brand, RM; Charron, AR; Henery, EM; Jendrzejewski, JL, 2006
)
0.33
" Previous research identified the need for the development of an effective dosage form for the systemic delivery of DMF due to its unique antiviral properties."( Development of an analytical method for the evaluation of N,N-dimethylformamide in dosage form design.
Du Toit, D; Hamman, JH; Olivier, EI, 2007
)
0.58
"The objective of the present work was to improve the dissolution properties of the poorly water-soluble drug meloxicam by preparing solid dispersions with hydroxyethyl cellulose (HEC), mannitol and polyethylene glycol (PEG) 4000 and to develop a dosage form for geriatric population."( Solid dispersion of meloxicam: factorially designed dosage form for geriatric population.
Dahiya, S; Pathak, D; Pathak, K, 2008
)
0.35
" While magnitudes of the hypertrophic and necrotic responses were linearly increased with an increase in amounts of DMF uptake in the single-route exposure groups, those dose-response relationships tended to level off in the combined-exposure groups."( Enhanced proliferative response of hepatocytes to combined inhalation and oral exposures to N,N-dimethylformamide in male rats.
Aiso, S; Fukushima, S; Nagano, K; Ohbayashi, H; Ohta, H; Yamazaki, K, 2008
)
0.56
"Biologically based dose-response (BBDR) modeling of environmental pollutants can be utilized to inform the mode of action (MOA) by which compounds elicit adverse health effects."( Development of a quantitative model incorporating key events in a hepatotoxic mode of action to predict tumor incidence.
Conolly, RB; DeVito, MJ; El-Masri, HA; Luke, NS; Sams, R, 2010
)
0.36
" At the optimal conditions of an alkali dosage of 40 g/L, an air/liquid ratio of 3000:1 and 5 h in the air-stripping process, the removal of total organic carbon and DMF was found to be 58% and 96%, respectively."( A novel chemical/biological combined technique for N, N-dimethylformamide wastewater treatment.
Chen, Y; Li, B; Qiu, Y; Shen, S; Xu, X, 2016
)
0.68
" Here, metabolic profiles for aniline (A), chloroform (CL), ethylbenzene (EB), 2-methoxyethanol (ME), N,N-dimethylformamide (DMF) and tetrahydrofurane (THF), dosed inhalatively for six hours/day, five days a week for 4 weeks were compared to oral dosing performed daily for 4 weeks."( Metabolite profiles of rats in repeated dose toxicological studies after oral and inhalative exposure.
Bordag, N; Fabian, E; Herold, M; Kamp, H; Krennrich, G; Looser, R; Ma-Hock, L; Mellert, W; Montoya, G; Peter, E; Prokudin, A; Spitzer, M; Strauss, V; van Ravenzwaay, B; Walk, T; Zbranek, R, 2016
)
0.65
" Few studies have assessed the dose-response relationships between internal exposure biomarkers and liver injury in DMF exposed populations."( A Comparative Benchmark Dose Study for N, N-Dimethylformamide Induced Liver Injury in a Chinese Occupational Cohort.
Cheng, J; Guan, M; Jiang, H; Jiang, X; Leng, S; Liu, Q; Wang, C; Wu, Z; Xu, B; Ye, M; Zhang, M; Zhao, W; Zheng, M, 2017
)
0.72
" These results suggest that electospun films from EtOH system may be a good candidate for fast-dissolving drug delivery systems to increase palatability of dosage forms."( Cyclodextrin-based oral dissolving films formulation of taste-masked meloxicam.
Akkaramongkolporn, P; Kaomongkolgit, R; Opanasopit, P; Samprasit, W, 2018
)
0.48
" Therefore, it is conceivable that a slight dosage of nitrate would enrich the abundance of DHB in both the UASB and the AnMBR, and provide a sufficient quantity of enzymes for the DMF hydrolysis."( A comparative long-term operation using up-flow anaerobic sludge blanket (UASB) and anaerobic membrane bioreactor (AnMBR) for the upgrading of anaerobic treatment of N, N-dimethylformamide-containing wastewater.
Kato, H; Kong, Z; Li, L; Li, YY; Wang, T; Xue, Y, 2020
)
0.75
" The discharge power, initial concentration of DMF, initial pH of the solution, and dosage of Mn-AC affect the removal of DMF."( Removal of N,N-dimethylformamide by dielectric barrier discharge plasma combine with manganese activated carbon.
Jin, X; Li, C; Li, M; Mei, L; Sang, W; Zhan, C; Zhang, Q; Zhang, S, 2021
)
0.97
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
polar aprotic solventA solvent with a comparatively high relative permittivity (or dielectric constant), greater than ca. 15, and a sizable permanent dipole moment, that cannot donate suitably labile hydrogen atoms to form strong hydrogen bonds.
hepatotoxic agentA role played by a chemical compound exihibiting itself through the ability to induce damage to the liver in animals.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
formamidesAmides with the general formula R(1)R(2)NCHO (R(1) and R(2) can be H).
volatile organic compoundAny organic compound having an initial boiling point less than or equal to 250 degreeC (482 degreeF) measured at a standard atmospheric pressure of 101.3 kPa.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
succinate to cytochrome bo oxidase electron transfer831
NADH to cytochrome bo oxidase electron transfer II526
D-lactate to cytochrome bo oxidase electron transfer527
glycerol-3-phosphate to cytochrome bo oxidase electron transfer529
proline to cytochrome bo oxidase electron transfer531
NADH to cytochrome bo oxidase electron transfer I1734
pyruvate to cytochrome bo oxidase electron transfer535

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.03980.001318.074339.8107AID926; AID938
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.01410.000214.376460.0339AID588532
retinoid X nuclear receptor alphaHomo sapiens (human)Potency14.12540.000817.505159.3239AID588544
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency6.30961.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear factor erythroid 2-related factor 2Homo sapiens (human)Activity1.50800.82001.82095.2700AID1420754; AID1420756; AID1420757; AID1420758; AID1420759
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
response to ischemiaNuclear factor erythroid 2-related factor 2Homo sapiens (human)
regulation of transcription by RNA polymerase IINuclear factor erythroid 2-related factor 2Homo sapiens (human)
inflammatory responseNuclear factor erythroid 2-related factor 2Homo sapiens (human)
response to oxidative stressNuclear factor erythroid 2-related factor 2Homo sapiens (human)
proteasomal ubiquitin-independent protein catabolic processNuclear factor erythroid 2-related factor 2Homo sapiens (human)
positive regulation of gene expressionNuclear factor erythroid 2-related factor 2Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic processNuclear factor erythroid 2-related factor 2Homo sapiens (human)
positive regulation of neuron projection developmentNuclear factor erythroid 2-related factor 2Homo sapiens (human)
protein ubiquitinationNuclear factor erythroid 2-related factor 2Homo sapiens (human)
positive regulation of blood coagulationNuclear factor erythroid 2-related factor 2Homo sapiens (human)
endoplasmic reticulum unfolded protein responseNuclear factor erythroid 2-related factor 2Homo sapiens (human)
cellular response to oxidative stressNuclear factor erythroid 2-related factor 2Homo sapiens (human)
PERK-mediated unfolded protein responseNuclear factor erythroid 2-related factor 2Homo sapiens (human)
cellular response to glucose starvationNuclear factor erythroid 2-related factor 2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNuclear factor erythroid 2-related factor 2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationNuclear factor erythroid 2-related factor 2Homo sapiens (human)
regulation of innate immune responseNuclear factor erythroid 2-related factor 2Homo sapiens (human)
cell redox homeostasisNuclear factor erythroid 2-related factor 2Homo sapiens (human)
positive regulation of angiogenesisNuclear factor erythroid 2-related factor 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear factor erythroid 2-related factor 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor erythroid 2-related factor 2Homo sapiens (human)
regulation of embryonic developmentNuclear factor erythroid 2-related factor 2Homo sapiens (human)
aflatoxin catabolic processNuclear factor erythroid 2-related factor 2Homo sapiens (human)
positive regulation of glucose importNuclear factor erythroid 2-related factor 2Homo sapiens (human)
cellular response to hydrogen peroxideNuclear factor erythroid 2-related factor 2Homo sapiens (human)
cellular response to copper ionNuclear factor erythroid 2-related factor 2Homo sapiens (human)
cellular response to tumor necrosis factorNuclear factor erythroid 2-related factor 2Homo sapiens (human)
cellular response to hypoxiaNuclear factor erythroid 2-related factor 2Homo sapiens (human)
cellular response to xenobiotic stimulusNuclear factor erythroid 2-related factor 2Homo sapiens (human)
cellular response to fluid shear stressNuclear factor erythroid 2-related factor 2Homo sapiens (human)
cellular response to laminar fluid shear stressNuclear factor erythroid 2-related factor 2Homo sapiens (human)
negative regulation of ferroptosisNuclear factor erythroid 2-related factor 2Homo sapiens (human)
integrated stress response signalingNuclear factor erythroid 2-related factor 2Homo sapiens (human)
negative regulation of cellular response to hypoxiaNuclear factor erythroid 2-related factor 2Homo sapiens (human)
regulation of cellular response to oxidative stressNuclear factor erythroid 2-related factor 2Homo sapiens (human)
negative regulation of hematopoietic stem cell differentiationNuclear factor erythroid 2-related factor 2Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayNuclear factor erythroid 2-related factor 2Homo sapiens (human)
positive regulation of glutathione biosynthetic processNuclear factor erythroid 2-related factor 2Homo sapiens (human)
positive regulation of ERAD pathwayNuclear factor erythroid 2-related factor 2Homo sapiens (human)
cellular response to angiotensinNuclear factor erythroid 2-related factor 2Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell migrationNuclear factor erythroid 2-related factor 2Homo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic processNuclear factor erythroid 2-related factor 2Homo sapiens (human)
regulation of removal of superoxide radicalsNuclear factor erythroid 2-related factor 2Homo sapiens (human)
negative regulation of endothelial cell apoptotic processNuclear factor erythroid 2-related factor 2Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processNuclear factor erythroid 2-related factor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingNuclear factor erythroid 2-related factor 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor erythroid 2-related factor 2Homo sapiens (human)
transcription coregulator bindingNuclear factor erythroid 2-related factor 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor erythroid 2-related factor 2Homo sapiens (human)
DNA bindingNuclear factor erythroid 2-related factor 2Homo sapiens (human)
DNA-binding transcription factor activityNuclear factor erythroid 2-related factor 2Homo sapiens (human)
protein bindingNuclear factor erythroid 2-related factor 2Homo sapiens (human)
protein domain specific bindingNuclear factor erythroid 2-related factor 2Homo sapiens (human)
ubiquitin protein ligase bindingNuclear factor erythroid 2-related factor 2Homo sapiens (human)
sequence-specific DNA bindingNuclear factor erythroid 2-related factor 2Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingNuclear factor erythroid 2-related factor 2Homo sapiens (human)
molecular condensate scaffold activityNuclear factor erythroid 2-related factor 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor erythroid 2-related factor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
mediator complexNuclear factor erythroid 2-related factor 2Homo sapiens (human)
non-membrane-bounded organelleNuclear factor erythroid 2-related factor 2Homo sapiens (human)
nucleusNuclear factor erythroid 2-related factor 2Homo sapiens (human)
nucleoplasmNuclear factor erythroid 2-related factor 2Homo sapiens (human)
cytoplasmNuclear factor erythroid 2-related factor 2Homo sapiens (human)
Golgi apparatusNuclear factor erythroid 2-related factor 2Homo sapiens (human)
centrosomeNuclear factor erythroid 2-related factor 2Homo sapiens (human)
cytosolNuclear factor erythroid 2-related factor 2Homo sapiens (human)
plasma membraneNuclear factor erythroid 2-related factor 2Homo sapiens (human)
RNA polymerase II transcription regulator complexNuclear factor erythroid 2-related factor 2Homo sapiens (human)
chromatinNuclear factor erythroid 2-related factor 2Homo sapiens (human)
protein-DNA complexNuclear factor erythroid 2-related factor 2Homo sapiens (human)
nucleusNuclear factor erythroid 2-related factor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (48)

Assay IDTitleYearJournalArticle
AID118807Antitumor activity was evaluated against the M5076 reticulum cell sarcoma in mice measured as mean tumor volume for the treated at the optimal dose 1000 mg/Kg/day1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structural studies on bioactive compounds. 4. A structure-antitumor activity study on analogues of N-methylformamide.
AID1321514Dissociation constant, pKa of the compound2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.
AID1306862Activation of Nrf2 in human HepG2 cells at 0.02 uM incubated for 12 hrs by ARE-driven luciferase reporter gene assay relative to control2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core.
AID110145Antitumor activity was evaluated against the M5076 reticulum cell sarcoma in mice measured as Control tumor volume for the treated at the optimal dose 1000 mg/Kg/day1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structural studies on bioactive compounds. 4. A structure-antitumor activity study on analogues of N-methylformamide.
AID1071717Antimicrobial activity against Aspergillus niger at 250 ug/disc after 5 to 7 days by well diffusion method2014European journal of medicinal chemistry, Mar-03, Volume: 74Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
AID476297Antibacterial activity against Staphylococcus capitis ATCC 2784 assessed as decrease in survival at 1.3 M by turbidimetric method2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Antibacterial effect of some benzopyrone derivatives.
AID1306853Cytoprotective activity against H2O2-induced cytotoxicity in rat PC12 cells assessed as cell viability pretreated at 20 uM for 24 hrs followed by H2O2 challenge for 12 hrs by MTT assay (Rvb = 50%)2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core.
AID386832Antibacterial activity against Escherichia coli at 100 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID1306845Cytotoxicity against human L02 cells assessed as cell viability at low to medium concentration after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core.
AID386840Antifungal activity against Aspergillus niger at 25 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID386836Antibacterial activity against Bacillus cirrhosis at 50 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID1306846Cytotoxicity against human NCM460 cells assessed as cell viability at low to medium concentration after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core.
AID1071719Antimicrobial activity against Bacillus subtilis at 250 ug/disc after 48 hrs by well diffusion method2014European journal of medicinal chemistry, Mar-03, Volume: 74Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
AID1420757Activation of Nrf2 in human HepG2-ARE-C8 cells assessed as induction of ARE-mediated luciferase activity at 1 uM after 24 hrs by luciferase reporter gene assay relative to control2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury.
AID386843Antifungal activity against Rhizoctonia bataticola at 25 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID386833Antibacterial activity against Escherichia coli at 50 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID1755220Activation of Nrf2 in mouse BV-2 cells assessed as upregulation of NQO-1 protein expression at 20 uM measured after 24 hrs by Western blot analysis2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Optimization of 1,4-bis(arylsulfonamido)naphthalene-N,N'-diacetic acids as inhibitors of Keap1-Nrf2 protein-protein interaction to suppress neuroinflammation.
AID1420760Activation of Nrf2 in human HepG2-ARE-C8 cells assessed as induction of ARE-mediated luciferase activity at 80 uM after 24 hrs by luciferase reporter gene assay relative to control2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury.
AID1306866Activation of Nrf2 in human HepG2 cells at 80 uM incubated for 12 hrs by ARE-driven luciferase reporter gene assay relative to control2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core.
AID1071718Antimicrobial activity against Escherichia coli at 250 ug/disc after 48 hrs by well diffusion method2014European journal of medicinal chemistry, Mar-03, Volume: 74Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
AID1306867Activation of Nrf2 in human HepG2 cells at 160 uM incubated for 12 hrs by ARE-driven luciferase reporter gene assay relative to control2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core.
AID386839Antifungal activity against Aspergillus niger at 50 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID1420758Activation of Nrf2 in human HepG2-ARE-C8 cells assessed as induction of ARE-mediated luciferase activity at 20 uM after 24 hrs by luciferase reporter gene assay relative to control2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury.
AID1420754Activation of Nrf2 in human HepG2-ARE-C8 cells assessed as induction of ARE-mediated luciferase activity at 0.01 uM after 24 hrs by luciferase reporter gene assay relative to control2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury.
AID1306863Activation of Nrf2 in human HepG2 cells at 0.2 uM incubated for 12 hrs by ARE-driven luciferase reporter gene assay relative to control2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core.
AID1306864Activation of Nrf2 in human HepG2 cells at 2 uM incubated for 12 hrs by ARE-driven luciferase reporter gene assay relative to control2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core.
AID1071716Antimicrobial activity against Aspergillus viridinutans at 250 ug/disc after 5 to 7 days by well diffusion method2014European journal of medicinal chemistry, Mar-03, Volume: 74Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
AID1306851Cytoprotective activity against H2O2-induced cytotoxicity in human L02 cells assessed as cell viability pretreated at 20 uM for 24 hrs followed by H2O2 challenge for 12 hrs by MTT assay (Rvb = 50%)2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1420759Activation of Nrf2 in human HepG2-ARE-C8 cells assessed as induction of ARE-mediated luciferase activity at 40 uM after 24 hrs by luciferase reporter gene assay relative to control2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury.
AID1420780Hepatoprotective activity against APAP-induced cell injury in human LO2 cells assessed as increase in cell viability at 20 uM pretreated for 24 hrs followed by APAP treatment measured after 24 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury.
AID116701Antitumor activity was evaluated against the M5076 reticulum cell sarcoma in mice at dose of 1500-600 mg/kg per day1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structural studies on bioactive compounds. 4. A structure-antitumor activity study on analogues of N-methylformamide.
AID476296Antibacterial activity against Staphylococcus capitis ATCC 2784 assessed as decrease in survival at 0.5 M by turbidimetric method2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Antibacterial effect of some benzopyrone derivatives.
AID386834Antibacterial activity against Escherichia coli at 25 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID1755219Activation of Nrf2 in mouse BV-2 cells assessed as upregulation of HO-1 protein expression at 20 uM measured after 24 hrs by Western blot analysis2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Optimization of 1,4-bis(arylsulfonamido)naphthalene-N,N'-diacetic acids as inhibitors of Keap1-Nrf2 protein-protein interaction to suppress neuroinflammation.
AID122265Antitumor activity was evaluated for the compound against the M5076 reticulum cell sarcoma in mice and the % T/C(treated/control) value was calculated at optimal dose of 1000 mg/kg1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structural studies on bioactive compounds. 4. A structure-antitumor activity study on analogues of N-methylformamide.
AID386837Antibacterial activity against Bacillus cirrhosis at 25 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID386842Antifungal activity against Rhizoctonia bataticola at 50 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID1306852Cytoprotective activity against H2O2-induced cytotoxicity in human NCM460 cells assessed as cell viability pretreated at 20 uM for 24 hrs followed by H2O2 challenge for 12 hrs by MTT assay (Rvb = 50%)2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core.
AID116885Antitumor activity was evaluated against the M5076 reticulum cell sarcoma in mice at dose of 1500-600 mg/kg per day1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structural studies on bioactive compounds. 4. A structure-antitumor activity study on analogues of N-methylformamide.
AID386841Antifungal activity against Rhizoctonia bataticola at 100 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID1420756Activation of Nrf2 in human HepG2-ARE-C8 cells assessed as induction of ARE-mediated luciferase activity at 0.1 uM after 24 hrs by luciferase reporter gene assay relative to control2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury.
AID386835Antibacterial activity against Bacillus cirrhosis at 100 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID386838Antifungal activity against Aspergillus niger at 100 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID1306847Cytotoxicity against rat PC12 cells assessed as cell viability at low to medium concentration after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core.
AID159270Toxicity determined using Microtox Test1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID1306861Activation of Nrf2 in human HepG2 cells at 20 uM incubated for 12 hrs by ARE-driven luciferase reporter gene assay relative to control2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core.
AID1306865Activation of Nrf2 in human HepG2 cells at 40 uM incubated for 12 hrs by ARE-driven luciferase reporter gene assay relative to control2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,799)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990659 (36.63)18.7374
1990's258 (14.34)18.2507
2000's342 (19.01)29.6817
2010's441 (24.51)24.3611
2020's99 (5.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 81.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index81.80 (24.57)
Research Supply Index7.56 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index148.41 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (81.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (0.21%)5.53%
Reviews34 (1.78%)6.00%
Case Studies31 (1.62%)4.05%
Observational0 (0.00%)0.25%
Other1,842 (96.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]